Xiuning Le MD PhD

📖 🔥 New online #firmonertinib in EGFR #PACC-mut NSCLC. @Cancer_Cell
👉 Firmonertinib has a trifluoroethoxy group, which enhances its potency against EGFR PACC mutation
👉 68% response rate with firmonertinib 240 mg daily.
Median progression-free survival of 16.0 months at 240 mg.
👉 47% intracranial response rate among patients with baseline brain metastases.
@EGFRResisters @Exon20Group @lungoncdoc @riess_md

😜 Are we ready for the era of #PD1×VEGF #bispecific immunotherapy? 📖 Now online in #LancetOncology: #HARMONi — #ivonescimab plus chemotherapy in patients with #EGFR-mutant #NSCLC after progression on EGFR TKI therapy.
👉 First global randomized phase 3 study of a PD1×VEGF bispecific antibody
N = 438, with 23% of patients enrolled in the United States
👉 Progression-free survival: 6.8 vs 4.4 months, HR 0.52
👉 Overall survival: 16.8 vs 14.0 months, HR 0.79
👉 Encouraging evidence of protection against CNS progression
💡 HARMONi represents an important step in evaluating the potential of simultaneously targeting PD-(L1)1 and VEGF. I hope this will be the first of many positive global studies exploring PD-(L)1 × VEGF approaches for patients with lung cancer and other solid tumors. lnkd.in/gUbwUxTb
❤️ my global col-investigators, @Tony_Calles @delvysra @MNagasaka @DrSanjayPopat @nicogirardcurie, Drs. Passaro, Cappuzzo, Zhang, and many others ❤️

📖 Now online @CD_AACR 🔥
👉 The oncogenic #EGFR–SHC1 #fusion drives hashtag#lungcancer through dual activation of the N-terminal EGFR kinase domain and C-terminal SHC1 phosphorylation sites. This biology requires combined inhibition of both EGFR and SRC-family kinases to achieve effective clinical control.
👉 Most importantly, this represents a novel fusion activation mechanism: SHC1 acts not merely as a facilitating #fusion partner, but as a true #collaborating partner in oncogenesis: a previously unrecognized mechanism with direct therapeutic implications.
👉 Could similar cooperative signaling by fusion partners help explain de novo or early resistance in other fusion-driven cancers? 😜
doi.org/10.1158/2159-8…
@ElizSMcKenna and Jurgen Wolf (University Hospital Cologne, Germany)

This is the amazing fifth @DAVAOnc Lung Summit meeting. 60% new faculties, topics were spanning from novel mechanistic discoveries to lastest FDA decsions, in all areas of #HNSCC and #NSCLC. @LaurenByersMD @fred_hirsch @maraantonoff @DasMillie11

📖 🔥New online from our group at @UTMDAnderson on ultra-precision oncology in #lungcancer
👉 Analysis from over 22,000 #EGFR-mutant tumor samples identified #PACC mutations in 12% of cases (A)
👉 While classical and #Ex20 mutations more commonly occur as single mutations, PACC mutations are more frequently (66%) observed as compound mutations (B).
👉 PACC/PACC and PACC/classical-like compound mutations function biologically similar to single PACC mutations, NOT classical mutations (C)
👉 Compound PACC mutations demonstrate greater sensitivity to EGFR TKIs than single PACC mutations (D)

⚡ 💡 Largest #EGFR mutation landscape in a Western population.
⚡ 💡 #Compound EGFR PACC Eare biologically analogous to #single PACC.
⚡ 💡 Important insights for drug development of next-generation EGFR TKIs.